A Phase I/IIa (Multi-center, Open-label, Phase I and Multi-center, Open-label, Phase IIa ) Study to Assess the Safety, Tolerability and Explore the Immunogenicity of EG-COVID and EG-COVARo in Healthy Adult Volunteers
EyeGene Inc.'s EG-COVID and EG-COVARo vaccines are positioned within the competitive landscape of COVID-19 vaccine development, focusing on safety, tolerability, and immunogenicity in healthy adults. Given the ongoing global demand for effective COVID-19 vaccines, particularly with emerging variants, successful outcomes could enhance EyeGene's market presence and potential partnerships. The study's completion in early 2025 may align with ongoing vaccination campaigns, providing a strategic entry point into the market. However, the competitive landscape remains robust, with established players and new entrants continually innovating, necessitating vigilance in market positioning and differentiation strategies.
Indication: COVID-19 Vaccine
Modality: RNA therapy
Target: SARS-CoV-2 spike protein (mRNA-based vaccines targeting COVID-19)
Sponsor: EyeGene Inc.
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 03, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: SARS-CoV-2 spike protein (mRNA-based vaccines targeting COVID-19)
View original source fields
Condition raw: COVID-19 Vaccine
Condition normalized: COVID-19 Vaccine
Modality raw: RNA therapy
Modality normalized: RNA therapy
Target raw: SARS-CoV-2 spike protein (mRNA-based vaccines targeting COVID-19)
Target normalized: SARS-CoV-2 spike protein (mRNA-based vaccines targeting COVID-19)